OTLC (Oncotelic Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


What is Oncotelic Therapeutics OCF Margin %?

Oncotelic Therapeutics OTLC -15.51% OCF Margin % is 0.00% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Oncotelic Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Oncotelic Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-0.34 Mil. Oncotelic Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Oncotelic Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Oncotelic Therapeutics's current OCF Yield % is -8.47%.

The historical rank and industry rank for Oncotelic Therapeutics's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Oncotelic Therapeutics was -161.52%. The lowest was -1887.14%. And the median was -1024.33%.

OTLC's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Oncotelic Therapeutics OCF Margin % Related Terms

Oncotelic Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Oncotelic Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncotelic Therapeutics OCF Margin % Chart

Oncotelic Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -1,887.14 0.00 0.00

Oncotelic Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oncotelic Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Oncotelic Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.383/0
= %

Oncotelic Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.342/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Oncotelic Therapeutics (OTLC) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oncotelic Therapeutics and its competitors. According to the industry distribution chart, Oncotelic Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Oncotelic Therapeutics' OCF Margin % too high?
Oncotelic Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Oncotelic Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Oncotelic Therapeutics' OCF Margin % compare to ALLR and MRKR?
According to the Biotechnology industry distribution chart, Oncotelic Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places Oncotelic Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oncotelic Therapeutics and its competitors. Oncotelic Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncotelic Therapeutics stock overvalued right now?
Oncotelic Therapeutics (OTLC) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Oncotelic Therapeutics (OTLC), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncotelic Therapeutics Business Description

Address 29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.